Namodenoson Treatment of Advanced Pancreatic Cancer
← catalyst calendarSponsored by Can-Fite BioPharma (industry) · CANF — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
1
Country
Israel
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-10 | actual | When the study began enrolling |
| Primary completion | 2026-07-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
Intervention
- Drug: Namodenoson 25mg — also filed as CF102
Primary outcomes
what the primary-completion date above is the date OFAdverse Events
measured Every 2 weeks, assessed up to 1 year
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline
measured Every 2 weeks, assessed up to 1 year
Publications
- PMID 26206252 — cited as background
- PMID 34750517 — cited as background
- PMID 19097774 — cited as background
- PMID 38002266 — cited as background
- PMID 28052758 — cited as background
- PMID 7165009 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CANF's whole pipeline · Catalyst calendar · Every registered study · What changed